BioLineRx (BLRX) Return on Equity [ROE] (2013 - 2026)
BioLineRx's Return on Equity [ROE] was -59.88% in the quarter ended Jun 30, 2026, down 18.09 percentage points from -41.79% a year earlier and down 10.92 percentage points from the prior quarter.
Powered by 
Analysis
BioLineRx (BLRX) Return on Equity [ROE] (2013 - 2026) Analysis & Trends
For the year ended Dec 31, 2025, Return on Equity [ROE] at BioLineRx came in at -11.01%, up 58.10 percentage points from the prior year.
- Return on Equity [ROE] shows a five-year change of +97.35 percentage points (years ended Dec 2020 to Dec 2025).
- In earlier years, Return on Equity [ROE] was -69.11% in the year ended Dec 31, 2024 (+120.12 pp), -189.23% in the year ended Dec 31, 2023 (-147.27 pp), -41.96% in the year ended Dec 31, 2022 (+18.08 pp) and -60.04% in the year ended Dec 31, 2021 (+48.32 pp).
- The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly Return on Equity [ROE] since the quarter ended Sep 30, 2024.
- Compared with a year earlier, Return on Equity [ROE] has declined for three straight quarters, with an average year-over-year change of +143.98 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Equity [ROE] over five years was the quarter ended Dec 31, 2024 (a gain of 431.43 percentage points); the worst was the quarter ended Dec 31, 2023 (a drop of 411.76 percentage points).
- Per Business Quant data, BLRX's Return on Equity [ROE] in the three quarters before the quarter ended Jun 30, 2026 was -48.96% (quarter ended Mar 31, 2026), -46.39% (quarter ended Dec 31, 2025) and -34.10% (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 25.32% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 7.21% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 84.40% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 21.39% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 83.75% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -18.38% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 4.97% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 22.24% |
| 10 | BioLineRx | 6.14 Bn | 6.14 Bn | 235,000.00 | -59.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.88% |
| Mar 31, 2026 | -48.96% |
| Dec 31, 2025 | -46.39% |
| Sep 30, 2025 | -34.10% |
| Jun 30, 2025 | -41.79% |
| Mar 31, 2025 | -24.07% |
| Dec 31, 2024 | -28.67% |
| Sep 30, 2024 | -197.98% |
| Jun 30, 2024 | -222.91% |
| Mar 31, 2024 | -374.14% |
| Dec 31, 2023 | -460.10% |
| Sep 30, 2023 | -284.01% |
| Jun 30, 2023 | -146.40% |
| Mar 31, 2023 | -73.24% |
| Dec 31, 2022 | -48.34% |
| Sep 30, 2022 | -41.71% |
| Jun 30, 2022 | -37.33% |
| Mar 31, 2022 | -33.14% |
| Dec 31, 2021 | -38.93% |
| Sep 30, 2021 | -47.98% |
API Access
BioLineRx Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BLRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "BLRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BLRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();